摘要
目的观察半乳糖化白蛋白磁性阿霉素纳米粒(ADR-GHMN)在正常肝脏中的靶向性, 并观察ADR-GHMN在全身各脏器的分布特征。方法使用放射示踪技术,用125I标记纳米粒。肝动脉注射,分别于注药后5、15、30、60、120 min处死,立即取肝、肾、心、肺、小肠、脾、及周围血作γ计数。结果半乳糖化白蛋白磁性阿霉素纳米粒在注射后5 min后最高,为15054.4 CPM/g,各时相前者的肝摄取率均为同时刻后者的2,3倍。两药在肝、肾、心、肺、小肠、脾、及周围血的分布有高度显著性(P<0.05)。结论半乳糖化白蛋白磁性阿霉素纳米粒在正常肝组织中有明显的主动靶向性,半乳糖化白蛋白磁性阿霉素纳米粒主要分布肝脏,其它的脏器含量少。
Objective: The aim of this study was to observe the hepatic targeting of Gal-HSA magnetic nanoparticles containing adriamycin and its effect of magnetic field application to targeting distribution of the in vivo. Methods: Abdominal exposure was carried out through a midline abdominal incision. A cannula was inserted into the hepatic artery and fixed up it. Using radioactive tracer technique, Gal-HSA magnetic nanoparticles containing adriamycin and human serum albumin magnetic nanoparticles containing adriamycin were labelled with 125I. 125I Gal-HSA magnetic nanoparticles containing adriamycin and 125I human serum albumin magnetic nanoparticles containing adriamycin were injected into hepatic artery (equivalent dose of free adriamycin 0.5 mg/kg ). At 5, 15, 30, 60, 120 minute after hepatic artery injection.the rat was sacrificed. The liver, kidney, heart, lung, small intestine, spleen and blood was analyzed for 125I-counts. Results: Gal-HSA magnetic nanoparticles containing adriamycin had arrived at maximum uptake quantity in liver after 5 minute, its uptake quantity were 15 054.4 CPM/g. There is remarkable difference between two drugs which distributed in liver, kidney, lung, spleen, heart small intestineand blood (P<0.05). Conclusion: Gal-HSA magnetic nanoparticles containing adriamycin in normal rat liver had remarkable hepatic targeting and good magnetic targeting. Dose which Gal-HSA magnetic nanoparticles containing adriamycin injected mainly distributed in liver.
出处
《中国医学工程》
2004年第4期5-7,共3页
China Medical Engineering
基金
国家"十五"863计划课题:"磁性纳米药物载体系统治疗肝脏恶性肿瘤研究"项目编号:2002AA214011
